Cargando…
Rapid Onset Severe Immune Thrombocytopenia following mRNA COVID-19 Vaccine in a Young Patient
The coronavirus disease 2019 (COVID-19) pandemic has affected millions of people around the world. Vaccination against COVID-19 has been approved for the following three vaccines in the United States: Pfizer-BioNTech, Moderna, and Janssen. Hematological complications of vaccination have been reporte...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027455/ https://www.ncbi.nlm.nih.gov/pubmed/36950529 http://dx.doi.org/10.1155/2023/7877536 |
_version_ | 1784909713007181824 |
---|---|
author | Avila, Jorge Degirmenci, Huseyin Berk Contreras Chavez, Pamela Battinelli, Elisabeth M. Fleisher, Jorge |
author_facet | Avila, Jorge Degirmenci, Huseyin Berk Contreras Chavez, Pamela Battinelli, Elisabeth M. Fleisher, Jorge |
author_sort | Avila, Jorge |
collection | PubMed |
description | The coronavirus disease 2019 (COVID-19) pandemic has affected millions of people around the world. Vaccination against COVID-19 has been approved for the following three vaccines in the United States: Pfizer-BioNTech, Moderna, and Janssen. Hematological complications of vaccination have been reported in the literature but remain as a rare phenomenon. We present the case of a patient who developed severe thrombocytopenia within twenty-four hours following the Pfizer-BioNTech vaccination. Commonly encountered differentials including heparin-induced thrombocytopenia and common viral etiologies were ruled out, and other causes such as drug reactions deemed unlikely as the etiology of this presentation after a broad workup. Nucleocapsid antibodies against COVID-19 were found to be positive which indicated that vaccination was at least the second encounter with this virus for our patient, which has been reported previously as the cause of immune thrombocytopenia (ITP), and this might be the culprit for sudden onset. He responded to the first-line ITP treatment with corticosteroids and intravenous immunoglobulin (IVIG) as evidenced by the fast recovery of platelet count and lack of recurrence of thrombocytopenia. |
format | Online Article Text |
id | pubmed-10027455 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-100274552023-03-21 Rapid Onset Severe Immune Thrombocytopenia following mRNA COVID-19 Vaccine in a Young Patient Avila, Jorge Degirmenci, Huseyin Berk Contreras Chavez, Pamela Battinelli, Elisabeth M. Fleisher, Jorge Case Rep Hematol Case Report The coronavirus disease 2019 (COVID-19) pandemic has affected millions of people around the world. Vaccination against COVID-19 has been approved for the following three vaccines in the United States: Pfizer-BioNTech, Moderna, and Janssen. Hematological complications of vaccination have been reported in the literature but remain as a rare phenomenon. We present the case of a patient who developed severe thrombocytopenia within twenty-four hours following the Pfizer-BioNTech vaccination. Commonly encountered differentials including heparin-induced thrombocytopenia and common viral etiologies were ruled out, and other causes such as drug reactions deemed unlikely as the etiology of this presentation after a broad workup. Nucleocapsid antibodies against COVID-19 were found to be positive which indicated that vaccination was at least the second encounter with this virus for our patient, which has been reported previously as the cause of immune thrombocytopenia (ITP), and this might be the culprit for sudden onset. He responded to the first-line ITP treatment with corticosteroids and intravenous immunoglobulin (IVIG) as evidenced by the fast recovery of platelet count and lack of recurrence of thrombocytopenia. Hindawi 2023-03-13 /pmc/articles/PMC10027455/ /pubmed/36950529 http://dx.doi.org/10.1155/2023/7877536 Text en Copyright © 2023 Jorge Avila et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Avila, Jorge Degirmenci, Huseyin Berk Contreras Chavez, Pamela Battinelli, Elisabeth M. Fleisher, Jorge Rapid Onset Severe Immune Thrombocytopenia following mRNA COVID-19 Vaccine in a Young Patient |
title | Rapid Onset Severe Immune Thrombocytopenia following mRNA COVID-19 Vaccine in a Young Patient |
title_full | Rapid Onset Severe Immune Thrombocytopenia following mRNA COVID-19 Vaccine in a Young Patient |
title_fullStr | Rapid Onset Severe Immune Thrombocytopenia following mRNA COVID-19 Vaccine in a Young Patient |
title_full_unstemmed | Rapid Onset Severe Immune Thrombocytopenia following mRNA COVID-19 Vaccine in a Young Patient |
title_short | Rapid Onset Severe Immune Thrombocytopenia following mRNA COVID-19 Vaccine in a Young Patient |
title_sort | rapid onset severe immune thrombocytopenia following mrna covid-19 vaccine in a young patient |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027455/ https://www.ncbi.nlm.nih.gov/pubmed/36950529 http://dx.doi.org/10.1155/2023/7877536 |
work_keys_str_mv | AT avilajorge rapidonsetsevereimmunethrombocytopeniafollowingmrnacovid19vaccineinayoungpatient AT degirmencihuseyinberk rapidonsetsevereimmunethrombocytopeniafollowingmrnacovid19vaccineinayoungpatient AT contreraschavezpamela rapidonsetsevereimmunethrombocytopeniafollowingmrnacovid19vaccineinayoungpatient AT battinellielisabethm rapidonsetsevereimmunethrombocytopeniafollowingmrnacovid19vaccineinayoungpatient AT fleisherjorge rapidonsetsevereimmunethrombocytopeniafollowingmrnacovid19vaccineinayoungpatient |